A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
Abstract Immunotherapy targeting immune checkpoint molecules, programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), using therapeutic antibodies has been widely used for some human malignancies in the last 5 years. A costimulatory receptor, PD-1, is expressed on T cells and suppresses effector fun...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0b6a85047df74aa79f76ad9d2aea9699 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0b6a85047df74aa79f76ad9d2aea9699 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0b6a85047df74aa79f76ad9d2aea96992021-12-02T15:06:12ZA canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma10.1038/s41598-017-09444-22045-2322https://doaj.org/article/0b6a85047df74aa79f76ad9d2aea96992017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09444-2https://doaj.org/toc/2045-2322Abstract Immunotherapy targeting immune checkpoint molecules, programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), using therapeutic antibodies has been widely used for some human malignancies in the last 5 years. A costimulatory receptor, PD-1, is expressed on T cells and suppresses effector functions when it binds to its ligand, PD-L1. Aberrant PD-L1 expression is reported in various human cancers and is considered an immune escape mechanism. Antibodies blocking the PD-1/PD-L1 axis induce antitumour responses in patients with malignant melanoma and other cancers. In dogs, no such clinical studies have been performed to date because of the lack of therapeutic antibodies that can be used in dogs. In this study, the immunomodulatory effects of c4G12, a canine-chimerised anti-PD-L1 monoclonal antibody, were evaluated in vitro, demonstrating significantly enhanced cytokine production and proliferation of dog peripheral blood mononuclear cells. A pilot clinical study was performed on seven dogs with oral malignant melanoma (OMM) and two with undifferentiated sarcoma. Objective antitumour responses were observed in one dog with OMM (14.3%, 1/7) and one with undifferentiated sarcoma (50.0%, 1/2) when c4G12 was given at 2 or 5 mg/kg, every 2 weeks. c4G12 could be a safe and effective treatment option for canine cancers.Naoya MaekawaSatoru KonnaiSatoshi TakagiYumiko KagawaTomohiro OkagawaAsami NishimoriRyoyo IkebuchiYusuke IzumiTatsuya DeguchiChie NakajimaYukinari KatoKeiichi YamamotoHidetoshi UemuraYasuhiko SuzukiShiro MurataKazuhiko OhashiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Naoya Maekawa Satoru Konnai Satoshi Takagi Yumiko Kagawa Tomohiro Okagawa Asami Nishimori Ryoyo Ikebuchi Yusuke Izumi Tatsuya Deguchi Chie Nakajima Yukinari Kato Keiichi Yamamoto Hidetoshi Uemura Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| description |
Abstract Immunotherapy targeting immune checkpoint molecules, programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), using therapeutic antibodies has been widely used for some human malignancies in the last 5 years. A costimulatory receptor, PD-1, is expressed on T cells and suppresses effector functions when it binds to its ligand, PD-L1. Aberrant PD-L1 expression is reported in various human cancers and is considered an immune escape mechanism. Antibodies blocking the PD-1/PD-L1 axis induce antitumour responses in patients with malignant melanoma and other cancers. In dogs, no such clinical studies have been performed to date because of the lack of therapeutic antibodies that can be used in dogs. In this study, the immunomodulatory effects of c4G12, a canine-chimerised anti-PD-L1 monoclonal antibody, were evaluated in vitro, demonstrating significantly enhanced cytokine production and proliferation of dog peripheral blood mononuclear cells. A pilot clinical study was performed on seven dogs with oral malignant melanoma (OMM) and two with undifferentiated sarcoma. Objective antitumour responses were observed in one dog with OMM (14.3%, 1/7) and one with undifferentiated sarcoma (50.0%, 1/2) when c4G12 was given at 2 or 5 mg/kg, every 2 weeks. c4G12 could be a safe and effective treatment option for canine cancers. |
| format |
article |
| author |
Naoya Maekawa Satoru Konnai Satoshi Takagi Yumiko Kagawa Tomohiro Okagawa Asami Nishimori Ryoyo Ikebuchi Yusuke Izumi Tatsuya Deguchi Chie Nakajima Yukinari Kato Keiichi Yamamoto Hidetoshi Uemura Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi |
| author_facet |
Naoya Maekawa Satoru Konnai Satoshi Takagi Yumiko Kagawa Tomohiro Okagawa Asami Nishimori Ryoyo Ikebuchi Yusuke Izumi Tatsuya Deguchi Chie Nakajima Yukinari Kato Keiichi Yamamoto Hidetoshi Uemura Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi |
| author_sort |
Naoya Maekawa |
| title |
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| title_short |
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| title_full |
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| title_fullStr |
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| title_full_unstemmed |
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| title_sort |
canine chimeric monoclonal antibody targeting pd-l1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/0b6a85047df74aa79f76ad9d2aea9699 |
| work_keys_str_mv |
AT naoyamaekawa acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT satorukonnai acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT satoshitakagi acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yumikokagawa acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT tomohirookagawa acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT asaminishimori acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT ryoyoikebuchi acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yusukeizumi acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT tatsuyadeguchi acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT chienakajima acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yukinarikato acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT keiichiyamamoto acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT hidetoshiuemura acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yasuhikosuzuki acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT shiromurata acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT kazuhikoohashi acaninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT naoyamaekawa caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT satorukonnai caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT satoshitakagi caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yumikokagawa caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT tomohirookagawa caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT asaminishimori caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT ryoyoikebuchi caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yusukeizumi caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT tatsuyadeguchi caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT chienakajima caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yukinarikato caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT keiichiyamamoto caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT hidetoshiuemura caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT yasuhikosuzuki caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT shiromurata caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma AT kazuhikoohashi caninechimericmonoclonalantibodytargetingpdl1anditsclinicalefficacyincanineoralmalignantmelanomaorundifferentiatedsarcoma |
| _version_ |
1718388560145416192 |